CJC1295 + Ipamorelin Disposable Pen

Growth hormone secretagogue and growth hormone releasing hormone (GHRH) analog blend. CJC-1295 No DAC is a synthetic GHRH analog that stimulates the anterior pituitary to release growth hormone (GH). Has a short half-life which leads to GH release in pulses, mimicking natural secretion patterns. Ipamorelin is a selective ghrelin receptor agonist (GHRP) that also stimulates GH release but without significant impact on cortisol or prolactin, and provides a synergistic boost when paired with CJC-1295 no DAC amplifying pulses.

Benefits

• Promotes fat metabolism (lipolysis)
• Supports lean muscle preservation and growth
• Accelerates tissue healing (muscle, tendon, ligament)
• Enhances exercise recovery and repair of microtrauma
• Improved collagen synthesis for skin elasticity
• Potential cosmetic/anti-aging applications studied in peptide medicine
• GH release is linked to improved sleep quality
• Possible improvements in energy, mood, and recovery from fatigue

What is the difference between CJC-1295 and CJC-1295 No DAC?

• CJC-1295 with DAC (Drug Affinity Complex) includes an added component (DAC) that allows the peptide to bind to albumin in the blood, dramatically extending its half-life (to 6-8 days). This means that a single injection can elevate growth hormone (GH) and IGF-1 for up to a week, providing a sustained GH release over many days. The major disadvantage of this manner of dosing is the risk of desensitization due to the constant sustained GH elevation.
• CJC-1295 No DAC is a shortened version of CJC-1295 DAC that has a much shorter half-life of only 30 minutes. However, its biological effects (GH pulse) last between 2 and 3 hours. Is typically administered 2-3 times per day to mimic natural pulsatile GH release (which more closely resembles the body’s natural secretion pattern). Less likely to lead to desensitization.

Possible Side Effects

• Injection site reactions (redness, swelling, and/or itching)
• Water retention (magnesium supplementation may reduce this)
• Bloating
• Mild fatigue or lethargy, usually immediately after dosing
• Headaches
• Flushing/Heat and/or a pins and needles sensation following dosing (can be mitigated by injecting as slowly as possible)
• May stimulate hunger
• Nausea
• Hives
• Dry mouth
• Hyperactivity
• Uncommon side effects: tingling or numbness in the extremities, joint pain or stiffness, lightheadedness or dizziness, nausea
• Rare: Hypersensitivity/allergic reactions; rash; difficulty breathing; excess GH-like symptoms (acromegaly-like features): only with very high or prolonged misuse

Interactions

• Insulin/Blood sugar regulation: may temporarily reduce insulin sensitivity
• May interact with insulin therapy or oral hypoglycemics (metformin, sulfonulureas); monitor blood sugar carefully
• Patients on thyroid medications may need dose adjustments
• GH influences conversion of T4 ———> T3
• High-dose or chronic corticosteroids (e.g. prednisone, dexamethasone) can blunt GH release, reducing efficacy
• GH-induced fluid retention may reduce effectiveness of diuretics or worsen blood pressure control
• Should be monitored in people on beta-blockers, ACE inhibitors, ARB’s or calcium channel blockers
• Estrogen can reduce IGF-1 levels, potentially dampening benefits of GH secretagogues
• Concurrent use with anabolic steroids, testosterone, SARMs, or other hormone therapies may cause synergistic effects on muscle growth, water retention, or joint stress
• May contribute to dizziness or fatigue that could be compounded with sedatives, alcohol, or sleep medications
• May synergize with GH-induced insulin resistance, causing unpredictable swings in blood sugar
• May worsen insulin resistance

Contraindications

• Do not use if pregnant or breastfeeding.
• Do not use with active cancer (including pituitary adenomas).
• Do not use with untreated hypothyroidism.
• Use caution with blood-sugar regulation; monitor closely.
• Risk of fluid overload, hypertension, or edema in those with severe cardiovascular disease
• Do not use with uncontrolled diabetes mellitus
• Do not use if you already have elevated GH/IGF-1 levels and/or acromegaly that make additional stimulation unsafe
• Do not use if you have advanced stages of chronic kidney disease
• Do not take if you have an unstable thyroid disorder
• Not for use in critically ill patients
• Do not use if you have an allergy to mannitol or other peptide components
• If you determine that you are hypersensitive to this peptide, discontinue use.